Fortress Biotech Inc Stock Price, News & Analysis

Fortress Biotech (NASDAQ: FBIO) announced that Dr. Lindsay A. Rosenwald, Chairman and CEO, will present at the H.C. Wainwright BioConnect Virtual Conference from January 10 to January 13, 2022. The presentation will be available for on-demand viewing on Fortress’ website starting January 10, 2022, at 7:00 a.m. EST, for 30 days. Fortress Biotech focuses on developing and commercializing biopharmaceutical products, with a diverse pipeline that includes seven marketed products and over 30 in development across oncology, rare diseases, and gene therapy.

Fortress Biotech (FBIO) celebrated its 10-year anniversary on the Nasdaq by ringing the closing bell on December 21, 2021. Chairman and CEO Lindsay A. Rosenwald highlighted the company's growth, boasting a 123% increase in net revenue year-over-year, totaling $21.1 million. Fortress has built a strong portfolio, including seven marketed pharmaceuticals and over 30 product candidates spanning oncology, gene therapy, and dermatology. Additionally, the company generated approximately $56.9 million from the sale of Caelum Biosciences to AstraZeneca, reinforcing its financial position.

Fortress Biotech announced the initiation of a Phase 2 clinical trial for Triplex, a cytomegalovirus (CMV) vaccine, targeting adults co-infected with HIV. Developed by City of Hope, the trial aims to assess the vaccine's safety and ability to elicit a CMV-specific immune response, potentially reducing CMV replication. A total of 90 participants will receive either the vaccine or a placebo over a 96-week study period. Previous studies show Triplex as safe and immunogenic, emphasizing its potential role in managing CMV-related complications in HIV patients.

Journey Medical (NASDAQ: DERM) reported net revenues of $19.6 million for Q3 2021, a 108% increase from $9.4 million in Q3 2020. The company completed its initial public offering, raising $31.2 million in net proceeds. Although the net loss for Q3 2021 was $10.6 million ($1.16 per share), this was an improvement compared to a net loss of $22.2 million ($2.43 per share) in Q3 2020. Journey Medical anticipates dosing the first patient in its Phase 3 clinical program for DFD-29 in Q1 2022 while expanding its leadership team.

Journey Medical Corporation (NASDAQ: DERM) announced its participation at the Benzinga Global Small Cap Conference, taking place virtually from December 8-9, 2021. CEO Claude Maraoui and CFO Ernie De Paolantonio will present a corporate overview on December 9 at 11:10 AM EST. They will also be available for one-on-one meetings during the conference. Journey Medical specializes in developing and commercializing products for dermatological conditions and was founded by Fortress Biotech (NASDAQ: FBIO).

Cyprium Therapeutics, a partner of Fortress Biotech (FBIO), has initiated a rolling submission of a New Drug Application (NDA) for CUTX-101 to the FDA for treating Menkes disease. The submission is expected to complete in mid-2022. Positive results from pivotal studies demonstrate CUTX-101's safety and efficacy, and the drug has received several FDA designations. If approved, CUTX-101 could be the first treatment for this rare disease, addressing a significant unmet need. Fortress stands to receive up to $20 million in milestones and continues to oversee CUTX-101's development.

Journey Medical Corporation (NASDAQ: DERM) has expanded its board of directors, admitting four new independent members: Jeffrey Paley, M.D., Justin Smith, Miranda Toledano, and Neil Herskowitz. This strategic move supports the company following its recent IPO. Executive Chairman Lindsay Rosenwald emphasized the new board members' extensive expertise in finance and dermatology, aiming to drive growth and commercialization of dermatological products. Journey Medical currently has seven marketed products and one in clinical development, indicating potential for future expansion.

Journey Medical Corporation (NASDAQ: DERM) has closed its initial public offering, successfully selling 3,520,000 shares at $10.00 each, raising gross proceeds of $35.2 million. The proceeds will be allocated towards general corporate purposes, including research and development, marketing, and potential acquisitions. The offering was managed by B. Riley Securities, with Roth Capital Partners as a co-manager. Journey Medical specializes in dermatological products and aims to leverage its capital for growth in the competitive pharmaceutical market.

Fortress Biotech (NASDAQ: FBIO) reported a remarkable 123% year-over-year increase in net revenue, reaching a record $21.1 million for Q3 2021. The company’s partner, Journey Medical Corporation, successfully launched its $35.2 million IPO. Fortress also received $56.9 million from AstraZeneca following its acquisition of Caelum Biosciences. Upcoming initiatives include a rolling NDA submission for CUTX-101 and top-line results for cosibelimab expected by year-end 2021. Operating expenses rose significantly, with R&D expenses totaling $28.1 million for the quarter.